iCAD Secures Chinese Regulatory Approval For Digital Mammography CAD Technology

SecondLook Digital CAD Technology Now Available in China with GE Digital Mammography Systems

NASHUA, N.H. – May 12, 2011 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, announces that it has secured regulatory approval for its SecondLook® Digital by the State Food and Drug Administration (SFDA) in the People’s Republic of China. The approval allows iCAD’s SecondLook Digital computer-aided detection (CAD) technology to be sold with GE Digital Mammography Systems in order to assist radiologists in distinguishing potential cancers from other anomalies on a mammogram.

“Across the globe, film-based mammography systems are being upgraded to the new standard-of-care, full-field digital mammography. Computer-aided detection is an important tool used in conjunction with digital mammography that highlights areas warranting closer evaluation,” said Ken Ferry, President and CEO of iCAD. “We are honored to now have regulatory approval to provide women in China with access to iCAD’s SecondLook technology and we look forward to working with GE Healthcare as our partner in the country.”

iCAD’s SecondLook Digital utilizes advanced pattern recognition technology and is extremely proficient in helping the radiologist detect subtle cancers, or those that are most likely to be missed. Using a sophisticated algorithm, the CAD software identifies and marks suspicious areas on a mammogram for the radiologist to review. As part of its regulatory approval in China, the product went through testing by the SFDA.

“We congratulate iCAD on securing regulatory approval for its SecondLook Digital CAD solution in the People’s Republic of China. GE Healthcare continues to make significant progress in providing solutions for breast cancer detection and diagnosis globally, and we are excited to now offer women in China the benefit of SecondLook Digital CAD as part of our mammography solution. These tools can potentially help healthcare professionals diagnose breast cancer at an earlier stage – which ultimately benefits the patient,” said David Caumartin, GE Healthcare’s General Manager Mammography.

CAD technology has been included in several peer-reviewed studies, including an article titled “Detection of Breast Cancer with Full-Field Digital Mammography and Computer-Aided Detection,” in the American Journal of Roentgenology (Volume 192, Issue 2). The study found the following:

- CAD with full-field digital mammography showed a high sensitivity in identifying cancers.
- The SecondLook CAD correctly marked 94% of biopsy-proven cancers.
- The sensitivity of iCAD’s SecondLook CAD was not dependent on the size of the tumor; it was equally accurate with small and large lesions.

SecondLook CAD for digital mammography was designed and developed using thousands of cancer and normal studies, providing a powerful digital CAD performance. More information can be found at www.icadmed.com.

About iCAD

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). iCAD recently acquired Xoft, Inc., developer of the Axxent® eBx™ electronic brachytherapy system (eBx). Axxent uses non-radioactive miniaturized X-ray tube technology and is FDA-cleared for treatment of early stage breast cancer, skin cancer and endometrial cancer. The Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT).

For more information, call (877) iCADnow or visit www.icadmed.com.

For iCAD, contact Darlene Deptula-Hicks at 603-882-5200 x7944, or via email at ddeptula@icadmed.com.

For Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at afields@lhai.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.